


1. (Currently amended) A compound of formula (I):



I

or a pharmaceutically acceptable salt thereof wherein:

W is ~~hydrogen~~, halogen, cyano, alkyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl;

R<sup>1</sup> is alkyl, alkynyl, cycloalkyl, heterocyclic, aralkyl, heteroaryl or heteroarylalkyl;

R<sup>2</sup> is SO<sub>2</sub>R<sup>3</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, C(=O)NR<sup>6</sup>R<sup>7</sup>, or C(=O)R<sup>8</sup>;

X is NR<sup>9</sup>R<sup>10</sup> or CR<sup>11</sup>R<sup>12</sup>R<sup>13</sup>;

R<sup>3</sup> is alkyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>14</sup> are each, independently, hydrogen, alkyl, alkynyl, cycloalkyl, heterocyclic, acyl, aryl, heteroaryl or heteroarylalkyl, wherein optionally R<sup>4</sup> and R<sup>5</sup> together, R<sup>6</sup> and R<sup>7</sup> together, or R<sup>9</sup> and R<sup>10</sup> together form a heterocycle incorporating the nitrogen atom;

R<sup>11</sup>, R<sup>12</sup> and R<sup>13</sup> are independently, hydrogen, alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or OR<sup>14</sup>, wherein R<sup>11</sup> and R<sup>12</sup> together optionally form a cycloalkyl attached in a spiro fashion, or a heterocycloalkyl attached in a spiro fashion, or a carbonyl group (C=O).

2. (Original) The compound according to Claim 1 wherein W is CN and R<sup>1</sup> is arylalkyl or heteroaryl.

3. (Original) The compound according to claim 1 wherein R<sup>1</sup> is a benzyl or thiophenyl.

4. (Original) The compound according to Claim 1 wherein X is -NR<sup>9</sup>R<sup>10</sup> and R<sup>9</sup> is H, alkyl, aralkyl or acyl and R<sup>10</sup> is heteroaryl or heteroarylalkyl.

5. (Original) The compound according to Claim 4 wherein R<sup>9</sup> is H, methyl, benzyl or -C(O)Me.

6. (Original) The compound according to Claim 4 wherein  $R^{10}$  is imidazolyl.
7. (Original) The compound according to Claim 1 wherein  $X = CR^{11}CR^{12}R^{13}$  and  $R^{11} = H$  or  $OH$ ;  $R^{12} = -OH, -OMe, =O$ , or substituted phenyl; and  $R^{13} =$  substituted imidazolyl.
8. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
9. (Original) The pharmaceutical composition according to Claim 8 further comprising at least one additional anticancer agent.

10. (Original) A compound according to Claim 1 selected from the group consisting of:

N-Benzyl-N-[6-cyano-8-(3H-imidazol-4-ylamino)-chroman-3-yl]-methanesulfonamide;

N-[3-(Benzyl methanesulfonylamino)-6-cyanochroman-8-yl]-N-(3H-imidazol-4-yl)acetamide;

N-Benzyl-N-{6-cyano-8-[(3H-imidazol-4-yl)-methyl-amino]-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-{8-[benzyl-(3H-imidazol-4-yl)-amino]-6-cyano-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-{6-cyano-8-[hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-{6-cyano-8-[methoxy-(3-methyl-3H-imidazol-4-yl)-methyl]-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-[6-cyano-8-(3-methyl-3H-imidazole-4-carbonyl)-chroman-3-yl]-methanesulfonamide;

N-Benzyl-N-{8-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-6-cyano-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-{6-cyano-8-[methyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-{6-cyano-8-[methyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-chroman-3-yl}-methanesulfonamide;

N-{6-Cyano-8-[(pyridin-4-ylmethyl)-amino]-chroman-3-yl}-N-thiophen-3-ylmethyl-methanesulfonamide;

N-[6-Cyano-8-(methyl-pyridin-4-ylmethyl-amino)-chroman-3-yl]-N-thiophen-3-ylmethyl-methanesulfonamide;

N-{6-Cyano-8-[(pyridin-3-ylmethyl)-amino]-chroman-3-yl}-N-thiophen-3-ylmethyl-methanesulfonamide;

N-[6-Cyano-8-(methyl-pyridin-3-ylmethyl-amino)-chroman-3-yl]-N-thiophen-3-ylmethyl-methanesulfonamide; and

N-{6-Cyano-8-[(3H-imidazol-4-ylmethyl)-amino]-chroman-3-yl}-N-thiophen-3-ylmethyl-methanesulfonamide;

or a pharmaceutically acceptable salt thereof.

11. (Original) A method of inhibiting farnesyl protein transferase which comprises administering to a mammalian subject in need thereof a compound of formula I in an amount effective to inhibit farnesyl transferase.

12. (Original) A method of inhibiting tumors in a mammal which comprises administering to a mammalian subject in need thereof an effective tumor inhibiting amount of a compound of Claim 1.

13. (Original) The method of Claim 12 further comprising administering to said mammal at least one other anticancer agent.

14. (Original) A method of treating cancer comprising administering to a mammalian subject in need thereof a pharmaceutically effective amount of a compound according to Claim 1.